文献速递创伤骨科运动医学关节外科

英国足踝血栓栓塞研究(UK-FATE)

UK Foot and Ankle Thromboembolism (UK-FATE).
PubMed 文献 · Bone Joint J · 2024-11-01

这项多中心前瞻性全国协作审计纳入英国68个中心的足踝手术或跟腱断裂治疗患者,90天症状性静脉血栓栓塞发生率为0.87%(95%CI 0.71至1.06),VTE相关死亡率为0.03%(95%CI 0.005至0.080)。化学预防用药差异明显,32.71%未接受化学预防;多变量分析显示足踝手术类型和ASA分级是VTE最强预测因素。

要点

  • 90天症状性VTE发生率为0.87%(95%CI 0.71至1.06),VTE相关死亡率为0.03%(95%CI 0.005至0.080)。
  • 化学预防用药差异明显,32.71%的患者未接受化学预防,最常用药物为低分子肝素(n=6,303;56.79%)。
  • 多变量分析显示,足踝手术类型和ASA分级是VTE最强预测因素;跟腱断裂和高ASA分级与90天症状性VTE显著相关。

核心结论

  • 足踝手术及跟腱断裂治疗中,90天症状性VTE发生率和VTE相关死亡率均较低。
  • 化学预防用药存在明显差异;与90天症状性VTE显著相关的风险因素为跟腱断裂和高ASA分级。

研究设计与样本

  • 多中心前瞻性全国协作审计,数据收集覆盖参与英国医院9个月内所有在手术室接受足踝手术或跟腱断裂治疗的患者。
  • 共纳入来自68个中心的13,569例患者,其中11,363例可供分析。
  • 采用单变量逻辑回归评估VTE与血栓预防的关联,采用多变量逻辑回归识别VTE风险的关键预测因素。

主要发现

  • 11,363例可供分析患者中,择期手术占44.79%(n=5,090),除外跟腱断裂的创伤占42.16%(n=4,791),急性糖尿病相关操作占3.50%(n=398),跟腱断裂手术占2.44%(n=277),跟腱断裂非手术治疗占7.10%(n=807)。
  • 共记录11种化学抗凝药,最常用为低分子肝素(n=6,303;56.79%);32.71%未接受化学预防。
  • VTE共99例,发生率0.87%(95%CI 0.71至1.06);VTE相关死亡率为0.03%(95%CI 0.005至0.080)。
  • 单变量分析显示,年龄增加和ASA分级增高与VTE风险升高相关,既往癌症、卒中或VTE病史亦与VTE风险升高相关。
  • 多变量分析显示,VTE最强预测因素为足踝手术类型和ASA分级。

关键数值与推荐

  • 90天症状性VTE发生率0.87%(95%CI 0.71至1.06);VTE相关死亡率0.03%(95%CI 0.005至0.080)。
  • 与90天症状性VTE显著相关的风险因素为跟腱断裂和高ASA分级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Venous thromboembolism (VTE) is a potential complication of foot and ankle surgery. There is a lack of agreement on contributing risk factors and chemical prophylaxis requirements. The primary outcome of this study was to analyze the 90-day incidence of symptomatic VTE and VTE-related mortality in patients undergoing foot and ankle surgery and Achilles tendon (TA) rupture. Secondary aims were to assess the variation in the provision of chemical prophylaxis and risk factors for VTE. METHODS: This was a multicentre, prospective national collaborative audit with data collection over nine months for all patients undergoing foot and ankle surgery in an operating theatre or TA rupture treatment, within participating UK hospitals. The association between VTE and thromboprophylaxis was assessed with a univariable logistic regression model. A multivariable logistic regression model was used to identify key predictors for the risk of VTE. RESULTS: A total of 13,569 patients were included from 68 sites. Overall, 11,363 patients were available for analysis: 44.79% were elective (n = 5,090), 42.16% were trauma excluding TA ruptures (n = 4,791), 3.50% were acute diabetic procedures (n = 398), 2.44% were TA ruptures undergoing surgery (n = 277), and 7.10% were TA ruptures treated nonoperatively (n = 807). In total, 11 chemical anticoagulants were recorded, with the most common agent being low-molecular-weight heparin (n = 6,303; 56.79%). A total of 32.71% received no chemical prophylaxis. There were 99 cases of VTE (incidence 0.87% (95% CI 0.71 to 1.06)). VTE-related mortality was 0.03% (95% CI 0.005 to 0.080). Univariable analysis showed that increased age and American Society of Anesthesiologists (ASA) grade had higher odds of VTE, as did having previous cancer, stroke, or history of VTE. On multivariable analysis, the strongest predictors for VTE were the type of foot and ankle procedure and ASA grade. CONCLUSION: The 90-day incidence of symptomatic VTE and mortality related to VTE is low in foot and ankle surgery and TA management. There was notable variability in the chemical prophylaxis used. The significant risk factors associated with 90-day symptomatic VTE were TA rupture and high ASA grade.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Mangwani J, Houchen-Wolloff L, Malhotra K, et al. UK Foot and Ankle Thromboembolism (UK-FATE). Bone Joint J. 2024. PMID: 39481430. doi:10.1302/0301-620X.106B11.BJJ-2024-0128.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。